Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 12/20 | 0.66 |
| ▸ | KDM4C | Q9H3R0 | 12/20 | 0.66 |
| ▸ | KDM5A | P29375 | 1/20 | 0.66 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.66 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.66 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 3/20 | 0.52 |
| ▸ | PPARD | Q03181 | 3/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28020165 | 0.98 | KDM4A (0.68) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL8213501 | 0.98 | KDM4A (0.68) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL219327 | 0.98 | KDM4A (0.68) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL5219324 | 0.98 | KDM4A (0.68) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL5530872 | 0.98 | KDM4A (0.68) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL6029256 | 0.98 | KDM4A (0.68) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL1176587 | 0.98 | KDM4A (0.68) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL3402761 | 0.98 | KDM4A (0.68) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL13286331 | 0.98 | KDM4A (0.68) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| Water SCHEMBL11318112 | 0.95 | KDM4A (0.66) | KDM4AKDM4CKDM5AKDM7APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491009-B1 | CYCLOPENTANECARBOXAMIDE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INT (DE) | 2017-07-05 | — | — | EP | disclosed |
| US-8614238-B2 | Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-24 | — | — | US | disclosed |
| US-20130053412-A1 | Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-28 | — | — | US | disclosed |
| EP-2491009-A1 | CYCLOPENTANECARBOXAMIDE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | Boehringer Ingelheim International GmbH (DE) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011048018-A1 | CYCLOPENTANECARBOXAMIDE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053412-A1 | Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use | CPT1A, FASN, CES1 | KDM4A 2734/4885KDM4C 3124/4885KDM5A 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.